Short description:
Cell-penetrating miniproteins
Drug notes:
5 undisclosed programs RD multiple cancers
Long description:
FogPharma is developing treatments for currently undruggable disease targets. Many drugs can be classified as monoclonal antibodies that cannot access the cell interior or as small molecules that lack specificity for interior targets. FogPharma is focusing on a new class of drugs - Helicon polypeptides - that combine the targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. The polypeptides designed by FogPharma have an alpha helical shape, which confers unique drug-like properties and greater stability. FogPharma evaluates thousands of new peptides weekly in biochemical and cell-based assays to select hits to develop. FogPharma’s lead product, FOG-001, targets β-catenin, which is commonly overactive in cancer.
Jobs:
Sr. Scientist, Machine Learning Cambridge, MA|26 days ago
Principal/Sr. Principal Associate Scientist, Cance... Cambridge, MA|36 days ago
Principal Associate Scientist, Peptide Screening a... Cambridge, MA|37 days ago
Associate Director, Quality Systems Cambridge, MA|37 days ago
Principal Data Product Engineer Cambridge, MA|50 days ago
Sr. Manager / Associate Director, Data Management Cambridge, MA or Remote|53 days ago
Sr.Data Scientist, Cheminformatics Cambridge, MA|68 days ago
Senior Director, Biochemistry and Biophysics Cambridge, MA|71 days ago
Medical Director / Senior Medical Director, Clinic... Cambridge, MA|74 days ago
Sr. Manager, Project Management Cambridge, MA|96 days ago